Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Company Overview

Monte Rosa Therapeutics (NASDAQ:GLUE) is a biotechnology company focused on the discovery and development of small-molecule therapies that harness targeted protein degradation to treat a broad range of diseases. The company’s approach centers on molecular glues and bifunctional degraders, which recruit the cell’s natural protein disposal machinery to selectively eliminate disease-causing proteins. Monte Rosa’s lead research areas include oncology and immunology, with a pipeline of discovery-stage programs designed to address both solid tumors and hematologic malignancies.

At the core of Monte Rosa’s efforts is a proprietary platform that integrates computational biology, chemoproteomics and medicinal chemistry. This platform allows rapid identification of novel degrader candidates and optimization of their pharmacologic properties. By combining high-throughput screening with machine learning algorithms, the company accelerates the translation of early-stage hits into development candidates, enabling a more efficient path to the clinic.

Since its founding in 2019, Monte Rosa has established collaborations and research partnerships with leading pharmaceutical and academic institutions to expand its target space and validate degrader modalities. The company’s research facilities are headquartered in Cambridge, Massachusetts, and it maintains a strategic research presence in the United Kingdom to leverage regional expertise and foster transatlantic scientific exchange.

Monte Rosa is led by a seasoned team of executives and scientific leaders with decades of experience in drug discovery, translational research and clinical development. The senior leadership includes professionals who have held key roles in both emerging biotech firms and established pharmaceutical companies, guiding the organization’s strategic vision and advancing its mission to develop transformative therapies for patients with unmet medical needs.

Key Stats

• Today's Range: $4.73 to $5.13
• 50-Day Range: $3.70 to $5.08
• 52-Week Range: $3.50 to $12.40
• Volume: 465,652 shs
• Average Volume: 1.08 million shs
• Market Capitalization: $305.70 million
• P/E Ratio: 62.13
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Moderate Buy

Monte Rosa Therapeutics Stock Analysis - MarketRank™

Monte Rosa Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 791st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Monte Rosa Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monte Rosa Therapeutics is 62.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monte Rosa Therapeutics is 62.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.27.

Price to Book Value per Share Ratio

Monte Rosa Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.29% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monte Rosa Therapeutics does not currently pay a dividend.

Dividend Growth

Monte Rosa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.29% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Monte Rosa Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.

Percentage Held by Institutions

79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLUE Stock Analysis - Frequently Asked Questions

How have GLUE shares performed this year?

Monte Rosa Therapeutics' stock was trading at $6.94 at the start of the year. Since then, GLUE stock has decreased by 28.2% and is now trading at $4.98.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings data on Thursday, May, 8th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.81. The business earned $84.93 million during the quarter, compared to analyst estimates of $13.57 million. Monte Rosa Therapeutics had a net margin of 3.86% and a trailing twelve-month return on equity of 2.65%.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monte Rosa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLUE
• CIK: 1826457
• Web: www.monterosatx.com
• Phone: 617-949-2643
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.33
• High Stock Price Target: $19.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +207.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 62.26
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.70 million
• Net Margins: 3.86%
• Pretax Margin: 5.93%
• Return on Equity: 2.65%
• Return on Assets: 1.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.61
• Quick Ratio: 5.61

Sales & Book Value

• Annual Sales: $75.62 million
• Price / Sales: 4.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.63 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 61,510,000
• Free Float: 57,512,000
• Market Cap: $306.32 million
• Optionable: Optionable
• Beta: 1.41